Arthneeti
Latest: Nureca Q2 FY27 results →All Q3 FY26 results →
N

Nureca

Q3 FY26

Nureca Q3 FY26 investor presentation: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Price₹321
Market cap₹306 Cr
P/E70.5
Updated16 Oct 2026
Read3 min read

Based on Nureca's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q3 FY26 revenue from operations: INR 540 million (27% YoY growth) - Q3 FY26 EBITDA: INR 54 million (314% YoY growth) - Q3 FY26 Profit After Tax (PAT): INR 37 million (233% YoY growth) - Q3 FY25 revenue from operations: INR 425 million - Q3 FY25 EBITDA: INR 25.4 million - Q3 FY25 PAT: INR -28 million - 9M 26 revenue: INR 1,536 million - 9M 26 EBITDA: INR 130 million - 9M 26 PAT: INR 82 million Q3 FY26 EBITDA: INR 54 Mn, 13% margin, representing 314% YoY growth (vs.

From Nureca's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Q3 FY26 revenue from operations: INR 540 million (27% YoY growth)
  • Q3 FY26 EBITDA: INR 54 million (314% YoY growth)
  • Q3 FY26 Profit After Tax (PAT): INR 37 million (233% YoY growth)
  • Q3 FY25 revenue from operations: INR 425 million
  • Q3 FY25 EBITDA: INR 25.4 million
  • Q3 FY25 PAT: INR -28 million
  • 9M 26 revenue: INR 1,536 million

2 more points from Nureca's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nureca said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Nureca Technologies Pvt Limited (wholly owned manufacturing subsidiary) started operations in April 2022.
  • Products manufactured include Blood Pressure Monitors, Nebulizers, Electric Massagers, Oral and Infrared Thermometers, Heating Pads, Orthopedic Cushions, Breast Pumps, Vaporizers, Stethoscopes, Soft Orthopedic Goods.
  • Certifications received: 13 CDSCO approvals, ISO 9001:2015, ISO 13485:2016 from Intertek, and USFDA 510K-exempt approval for 7 products.

Fundraising & Capital Structure

See what Nureca said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Nureca said on order book & pipeline — free account, 30 seconds.

Nureca — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹59 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Nureca Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • QMS Medical Allied Services Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how

  • Tarsons Products Ltd (Q3 FY26)

    Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026. Key concall takeaways from Tarsons…

  • Poly Medicure Ltd (Q3 FY26)

    New acquisitions and subsidiaries, such as Plan1 Health (oncology business), are contributing significant growth (e.g., 30-35% year-on-year for Plan1 Health)…

  • Laxmi Dental Ltd (Q3 FY26)

    Scanner sales growth to continue, with digital penetration in India planned to increase from 79% to 90%, driving future expansion. Key concall takeaways from…

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nureca and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nureca Q3 FY26 results?

Q3 FY26 revenue from operations: INR 540 million (27% YoY growth) - Q3 FY26 EBITDA: INR 54 million (314% YoY growth) - Q3 FY26 Profit After Tax (PAT): INR 37 million (233% YoY growth) - Q3 FY25 revenue from operations: INR 425 million - Q3 FY25 EBITDA: INR 25.4 million - Q3 FY25 PAT: INR -28 million - 9M 26 revenue: INR 1,536 million - 9M 26 EBITDA: INR 130 million - 9M 26 PAT: INR 82 million Q3 FY26 EBITDA: INR 54 Mn, 13% margin, representing 314% YoY growth (vs.

What is Nureca share price analysis?

Nureca currently shows a neutral. The stock trades at a P/E of 70.5 with a market cap of ₹306 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nureca planning capital expenditure?

Nureca Technologies Pvt Limited (wholly owned manufacturing subsidiary) started operations in April 2022.

Keep Nureca on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.